Conduct research on nicotinamide adenine dinucleotide (NAD+) and its role in healthy aging. Develop proprietary formulations aimed at boosting NAD+ levels in the body. Now — the numbers.
This is an established company with proven profits.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 13.9× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 78% of them.
Analysts' average target sits 240% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 79% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 18% a year on average.
There is $64.8M in the vault; even if every debt were paid off, $62.0M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 21/100. For a turnaround signal, the stock first needs to close the gap with the market.
The share set aside for the future is small; the pace of new ideas may slow.
On our five-subject report card, NAGE sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: NAGE is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
Not covered, because the filings we hold do not carry it: the revenue breakdown.